Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs

Cummings, 2002, Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs, Am. J. Med., 112, 281, 10.1016/S0002-9343(01)01124-X Glorieux, 1998, Cyclic administration of pamidronate in children with severe osteogenesis imperfecta, N. Engl. J. Med., 339, 947, 10.1056/NEJM199810013391402 Saag, 1998, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group, N. Engl. J. Med., 339, 292, 10.1056/NEJM199807303390502 Fleisch, 2002, Bisphosphonates: mechanisms of action, 1361 Hughes, 1995, Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo, J. Bone Miner. Res., 10, 1478, 10.1002/jbmr.5650101008 Plotkin, 1999, Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, J. Clin. Invest., 104, 1363, 10.1172/JCI6800 Marotti, 1990, Structure–function relationships in the osteocyte, Ital. J. Miner. Electrolyte Metab., 4, 93 Nijweide, 1996, The osteocyte, 115 Rogers, 2000, Cellular and molecular mechanisms of action of bisphosphonates, Cancer, 88, 2961, 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L Luckman, 1998, Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras, J. Bone Miner. Res., 13, 581, 10.1359/jbmr.1998.13.4.581 Van Beek, 1996, Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group, J. Bone Miner. Res., 11, 1492, 10.1002/jbmr.5650111016 Plotkin, 2002, Transduction of cell survival signals by connexin-43 hemichannels, J. Biol. Chem., 277, 8648, 10.1074/jbc.M108625200 Rogers, 2004, From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates, Calcif. Tissue Int., 75, 451, 10.1007/s00223-004-0024-1 Liu, 2004, Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k, J. Bone Miner. Res., 19, 479, 10.1359/JBMR.0301242 Lecanda, 1998, Gap junctional communication modulates gene expression in osteoblastic cells, Mol. Biol. Cell, 9, 2249, 10.1091/mbc.9.8.2249 Kousteni, 2001, Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity, Cell, 104, 719 Bellido, 2003, Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism, J. Biol. Chem., 278, 50259, 10.1074/jbc.M307444200 Weinstein, 2002, Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids, J. Clin. Invest., 109, 1041, 10.1172/JCI0214538 Chen, 2005, Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti- versus pro-apoptotic effects of estrogens, J. Biol. Chem., 280, 4632, 10.1074/jbc.M411530200 Yan, 2001, Regulation of osteoclastogenesis and RANK expression by TGF-beta1, J. Cell. Biochem., 83, 320, 10.1002/jcb.1200 Grove, 2000, The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase, J. Bone Miner. Res., 15, 971, 10.1359/jbmr.2000.15.5.971 Dunford, 2001, Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J. Pharmacol. Exp. Ther., 296, 235 van Beek, 2003, Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates, Bone, 33, 805, 10.1016/j.bone.2003.07.007 Montalvetti, 2003, Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies, J. Biol. Chem., 278, 17075, 10.1074/jbc.M210467200 Sanders, 2003, 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates, J. Med. Chem., 46, 5171, 10.1021/jm0302344 Hsu, 1999, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proc. Natl. Acad. Sci. U. S. A., 96, 3540, 10.1073/pnas.96.7.3540 Huang, 2000, Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation, Am. J. Pathol., 156, 761, 10.1016/S0002-9440(10)64942-5 Kogianni, 2004, Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis, Life Sci., 75, 2879, 10.1016/j.lfs.2004.04.048 Brown, 1998, Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum, J. Bone Miner. Res., 13, 253, 10.1359/jbmr.1998.13.2.253 Ilvesaro, 2000, Bone-resorbing osteoclasts contain gap-junctional connexin-43, J. Bone Miner. Res., 15, 919, 10.1359/jbmr.2000.15.5.919 Manolagas, 2000, Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis, Endocr. Rev., 21, 115, 10.1210/er.21.2.115 Boyce, 2002, Apoptosis in bone cells, 151 Kousteni, 2002, Reversal of bone loss in mice by nongenotropic signaling of sex steroids, Science, 298, 843, 10.1126/science.1074935 Tomkinson, 1998, The role of estrogen in the control of rat osteocyte apoptosis, J. Bone Miner. Res., 13, 1243, 10.1359/jbmr.1998.13.8.1243 Jilka, 1999, Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone, J. Clin. Invest., 104, 439, 10.1172/JCI6610 Martin, 2005, Osteoblast-derived PTHrP is a physiological regulator of bone formation, J. Clin. Invest., 115, 2322, 10.1172/JCI26239 Miao, 2005, Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34, J. Clin. Invest., 115, 2402, 10.1172/JCI24918 O'Brien, 2004, Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength, Endocrinology, 145, 1835, 10.1210/en.2003-0990 Brumsen, 1997, Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis, Medicine (Baltimore), 76, 266, 10.1097/00005792-199707000-00005 Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J. Clin. Invest., 100, 1475, 10.1172/JCI119668 Balena, 1993, The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates, J. Clin. Invest., 92, 2577, 10.1172/JCI116872 Storm, 1993, Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis, J. Bone Miner. Res., 8, 199, 10.1002/jbmr.5650080211 Horie, 2003, Clodronate stimulates bone formation as well as inhibits bone resorption and increases bone mineral density in rats fed a low-calcium diet, J. Med. Dent. Sci., 50, 121 Borah, 2002, Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography, J. Bone Miner. Res., 17, 1139, 10.1359/jbmr.2002.17.7.1139 Borah, 2004, Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography, Bone, 34, 736, 10.1016/j.bone.2003.12.013 Geng, 2000, Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure, Clin. Nephrol., 54, 45 Hu, 2002, Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone, Bone, 31, 591, 10.1016/S8756-3282(02)00870-0 Mashiba, 2001, Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles, Bone, 28, 524, 10.1016/S8756-3282(01)00414-8